BEIGF:OTCMKTS
BeOne Medicines
21,95 USD
0,00%
(0,00) 1D
9-июн., 12:49:46 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BEIGF...
Mkt. cap
42,40 млд
Avg. vol.
0,00
Volume
0,00
52-wk high
24,92 USD
52-wk low
21,95 USD
Beta
0,84
Shares outstanding
1,43 млд
No. of employees
12 миң
Mkt. cap
42,40 млд
Avg. vol.
0,00
Volume
0,00
52-wk high
24,92 USD
52-wk low
21,95 USD
Beta
0,84
Shares outstanding
1,43 млд
No. of employees
12 миң
News stories
From web sources and news partners
MarketBeat
·
9 мүнөт мурун
Okta (NASDAQ:OKTA) Reaches New 12-Month High - Still a Buy?
Seeking Alpha
·
24 мүнөт мурун
QQQI: A Near-Term Nasdaq Pullback Does Not End The Bull Case
Yahoo Finance
·
13 саат мурун
Not Sandisk, Not Intel. This Stock Will Lead the S&P 500 Next Year
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines
CEOJohn Vincent Oyler | John Vincent Oyler
Employees12 миң
Founded2010-ж., 28-окт.
Headquarters-
Sector-
Websitebeonemedicines.com